ClearPoint Neuro (CLPT) Scheduled to Post Quarterly Earnings on Tuesday

ClearPoint Neuro (NASDAQ:CLPT) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect ClearPoint Neuro to post earnings of ($0.19) per share for the quarter. ClearPoint Neuro has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. ClearPoint Neuro had a negative net margin of 92.21% and a negative return on equity of 83.94%. The firm had revenue of $6.81 million for the quarter, compared to analyst estimates of $6.40 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Performance

Shares of CLPT stock traded down $0.01 during mid-day trading on Tuesday, hitting $5.32. 7,179 shares of the stock were exchanged, compared to its average volume of 143,975. The stock’s fifty day simple moving average is $6.42 and its two-hundred day simple moving average is $6.36. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.80 and a current ratio of 4.87. ClearPoint Neuro has a 12-month low of $4.05 and a 12-month high of $10.57. The stock has a market capitalization of $144.01 million, a price-to-earnings ratio of -5.86 and a beta of 0.89.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus restated a “buy” rating and set a $9.00 price target (up previously from $8.00) on shares of ClearPoint Neuro in a research note on Wednesday, March 13th.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.